CLINICAL FEATURES, TREATMENT RESPONSES, AND OUTCOME OF CHILDREN WITH IDIOPATHIC THROMBOCYTOPENIC PURPURA


Demircioglu F., Saygi M., YILMAZ Ş., ÖREN H., Irken G.

PEDIATRIC HEMATOLOGY AND ONCOLOGY, vol.26, no.7, pp.526-532, 2009 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 26 Issue: 7
  • Publication Date: 2009
  • Doi Number: 10.1080/08880010903044540
  • Journal Name: PEDIATRIC HEMATOLOGY AND ONCOLOGY
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.526-532
  • Keywords: high-dose methylprednisolone, immune thrombocytopenic purpura, intravenous immunoglobulin, vaccination, INTRAVENOUS IMMUNOGLOBULIN, MEGADOSE METHYLPREDNISOLONE, IMMUNE THROMBOCYTOPENIA, CHILDHOOD, MANAGEMENT, ITP
  • Dokuz Eylül University Affiliated: Yes

Abstract

The authors investigated demographics, clinical and laboratory features, treatment responses, and outcomes of 93 children (median age 5 years) admitted for idiopathic thrombocytopenic purpura (ITP). The therapy responses of high-dose methylprednisolone (HDMP) (n = 77) and intravenous immunoglobulin (IVIG) (n = 10) treatments were similar. None of the patients with hemorrhage died. Fifteen patients (16.1%) had progressed into chronic ITP. Seven infants had a probable relationship with vaccination; none of these infants progressed into chronic ITP. In conclusion, the overall prognosis in childhood ITP is good. The therapy responses of HDMP and IVIG treatments are similar. Also, ITP cases who havw vaccination history have a benign course.